SCHEMBL23999965

SCHEMBL23999965

C#Cc1ccc2nccc(Cl)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.46
DYRK1B Q9Y463 1/20 0.40
NR4A2 P43354 1/20 0.40
KDM4E B2RXH2 2/20 0.39
MAPT P10636 2/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MEN1 O00255 1/20 0.39
MAPK1 P28482 1/20 0.39
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30369707 0.82 PDE5A (0.49) DYRK1BNR4A2AXLPRKCIPDE5A
SCHEMBL730084 0.82 PDE5A (0.49) DYRK1BNR4A2AXLPRKCIPDE5A
SCHEMBL16289308 0.79 GABRA1 (0.39) EGFRNR4A2KDM4EMAPTALDH1A1
SCHEMBL16289311 0.79 SMN1; SMN2 (0.47) EGFRKDM4EMAPTALDH1A1HPGD
SCHEMBL25821855 0.77 PDE5A (0.38) EGFRDYRK1BNR4A2KDM4EMAPT
SCHEMBL26317737 0.76 GAK (0.50) EGFRMAPTALDH1A1PDE5ADOT1L
SCHEMBL23999836 0.76 MAP3K14 (0.40) EGFRDYRK1BNR4A2ALDH1A1CYP1A2
SCHEMBL26634008 0.75 PGK1 (0.41) DYRK1BNR4A2KDM4EMAPTALDH1A1
SCHEMBL30051309 0.75 NR4A2 (0.66) DYRK1BNR4A2MAPTALDH1A1CYP1A2
SCHEMBL1888577 0.75 NR4A2 (0.66) DYRK1BNR4A2MAPTALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219927-A1 AKT3 MODULATORS Georgiamune Inc. 2023-07-13 US disclosed
US-20230219927-A1 AKT3 MODULATORS Georgiamune Inc. 2023-07-13 US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 US disclosed
WO-2023081854-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 WO disclosed
WO-2021226458-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 WO disclosed
WO-2021226519-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183226-A1 AKT3 MODULATORS AKT3, AKT2, MTOR EGFR 1128/4885DYRK1B 3497/4885NR4A2 2808/4885
US-20230219927-A1 AKT3 MODULATORS AKT3, AKT2, PIK3CA EGFR 1176/4885DYRK1B 4073/4885NR4A2 2025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.